Please wait. Loading...
 

Δημοσιεύσεις

Κατευθυντήριες Οδηγίες

  • Κατεβάστε σε μορφή pdf τις Αναθεωρημένες Κατευθυντήριες Οδηγίες της Ευρωπαικής Εταιρίας Υπέρτασης - 2009.
     
  • American Heart Association Learn and Live 2009 STEMI and PCI Focused Update
     

Newsletter

Εγγραφείτε στο Newsletter μας και μάθετε πρώτοι τα νέα και τις επερχόμενες επιστημονικές εκδηλώσεις της εταιρίας.

  •  

Με την ευγενική χορηγία:

CHIESI HELLAS


SANOFI

Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial

John J.V. McMurray, MB, MD,a James B. Young, MD,b Mark E. Dunlap, MD,c Christopher B. Granger, MD,d James Hainer, MD,e Eric L. Michelson, MD,e Steven Earle, PhD,e Bertil Olofsson, PhD,f Jan O¨ stergren, MD,g Salim Yusuf, MD, DPhil,h Karl Swedberg, MD, PhD,i and Marc A. Pfeffer, MD, PhD,j on behalf of the CHARM Investigators Glasgow, Scotland; Cleveland, OH; Durham, NC; Wilmington, DE; Mo¨lndal, Stockholm, and Go¨teborg, Sweden; Hamilton, Ontario, Canada; and Boston, MA  

Background: Whether an angiotensin receptor blocker is of benefit when added to a full dose of angiotensinconverting enzyme (ACE) inhibitor in heart failure (HF) is uncertain.

Methods: The effect of candesartan, compared with placebo, in 2548 patients randomized in the CHARM-Added trial was analyzed according to (i) ACE inhibitor dose at baseline, (ii) ACE inhibitor dose during follow-up, and (iii) combination treatment with ACE inhibitor and h-blocker at baseline. The main outcome was the composite of cardiovascular death or HF hospitalization.

Results: The benefit of candesartan was not modified by the dose of ACE inhibitor. In all patients (n = 2548), the candesartan/placebo hazard ratio (HR) for the primary outcome was 0.85 (95% CI 0.75-0.96). In patients taking a guideline recommended dose of ACE inhibitor at baseline (n = 1291), this HR was 0.79 (95% CI 0.67-0.95; interaction P value .26). In patients taking a Food and Drug Administration-designated maximum dose of ACE inhibitor (n = 529), this HR was 0.75 (95% CI 0.57-0.98; interaction P value .29). The benefit of candesartan was preserved in patients taking h-blockers in addition to a higher dose of ACE inhibitor and in patients maintaining a high dose of ACE inhibitor throughout follow-up.

Conclusions: These clinical findings support the pharmacologic evidence that ACE inhibitors and angiotensin receptor blockers have distinct mechanisms of action and show that their combined use improves outcomes in patients with HF more than an evidence-based dose of ACE inhibitor alone. (Am Heart J 2006;151:99228.)

Κατεβάστε την ολοκληρωμένη δημοσίευση σε μορφή pdf.

 

 

© 2010-2014 Hellenic Society of Cardiovascular Prevention. All rights reserved.